Cargando…

Individual recurrence intervals after anti-VEGF therapy for age-related macular degeneration

BACKGROUND: To assess the time interval to recurrent choroidal neovascular membrane (CNV) activity in eyes with neovascular age-related macular degeneration (AMD) after intravitreal anti-VEGF therapy. METHODS: Data from all patients who received intravitreal ranibizumab injections for neovascular AM...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hörster, Robert, Ristau, Tina, Sadda, Srinivas R., Liakopoulos, Sandra
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2010
Materias:	Retinal Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084429/ https://www.ncbi.nlm.nih.gov/pubmed/21170547 http://dx.doi.org/10.1007/s00417-010-1588-2

Ejemplares similares

Cost-minimisation analysis of a treat-and-extend regimen with anti-VEGFs in patients with neovascular age-related macular degeneration
por: Quist, S. W., et al.
Publicado: (2021)

Refractory neovascular age-related macular degeneration: time-dependent changes of central retinal thickness with anti-VEGF treatment
por: Zola, Marta, et al.
Publicado: (2020)

Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis
por: Sadda, SriniVas, et al.
Publicado: (2022)

Relationship between the distribution of intra-retinal hyper-reflective foci and the progression of intermediate age-related macular degeneration
por: Verma, Aditya, et al.
Publicado: (2023)

Disease stability and extended dosing under anti-VEGF treatment of exudative age-related macular degeneration (AMD) — a meta-analysis
por: Garweg, Justus G., et al.
Publicado: (2021)

Evolution of macular atrophy in eyes with neovascular age-related macular degeneration compared to fellow non-neovascular eyes
por: Blazaki, Styliani, et al.
Publicado: (2023)

Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
por: Hanhart, Joel, et al.
Publicado: (2022)

Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy
por: Mikhail, Michael, et al.
Publicado: (2018)

Near-infrared reflectance imaging of neovascular age-related macular degeneration
por: Theelen, Thomas, et al.
Publicado: (2009)

Effects of suspension of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration in clinical setting
por: Matsubara, Hisashi, et al.
Publicado: (2022)

Effects of cataract surgery in Japanese patients with neovascular age-related macular degeneration
por: Nishiguchi, Fumi, et al.
Publicado: (2020)

Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR
por: Freund, K. Bailey, et al.
Publicado: (2022)

Comparison of swept-source versus spectral-domain optical coherence tomography angiography for detection of macular neovascularization
por: Lentzsch, Anna, et al.
Publicado: (2021)

Prechoroidal cleft thickness correlates with disease activity in neovascular age-related macular degeneration
por: Cozzi, Mariano, et al.
Publicado: (2021)

Retinal venous pressure is decreased after anti-VEGF therapy in patients with retinal vein occlusion–related macular edema
por: Kida, Teruyo, et al.
Publicado: (2021)

Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
por: Marquis, Liza-Marie, et al.
Publicado: (2020)

Real-life study of the use of anti-VEGF therapy versus dexamethasone implant for treatment of macular edema in retinal vein occlusion
por: de Salles, Manuel Casselholm, et al.
Publicado: (2021)

Treatment contentment and preference of patients undergoing intravitreal anti-VEGF therapy
por: Kellner, Ulrich, et al.
Publicado: (2021)

Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration treated with Aflibercept
por: Parvin, Parmis, et al.
Publicado: (2017)

Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration
por: Pellegrini, Marco, et al.
Publicado: (2020)

Association of imaging biomarkers and local activation of complement in aqueous humor of patients with early forms of age-related macular degeneration
por: Sitnilska, Vasilena, et al.
Publicado: (2020)

Evaluating an automated machine learning model that predicts visual acuity outcomes in patients with neovascular age-related macular degeneration
por: Abbas, Abdallah, et al.
Publicado: (2022)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Five-year cumulative incidence and progression of age-related macular degeneration: results from the German population-based Gutenberg Health Study (GHS)
por: Korb, Christina A., et al.
Publicado: (2021)

Association of autoantibody levels with different stages of age-related macular degeneration (AMD): Results from the population-based Gutenberg Health Study (GHS)
por: Korb, Christina A., et al.
Publicado: (2023)

See clearer: survey on the subjective and objective information levels as well as perception and information transfer using virtual reality headsets in patients with diabetic macular edema receiving anti-VEGF treatment
por: Enders, Christian, et al.
Publicado: (2022)

Retinal pigment epithelium hyperplasia overlying pigment epithelial detachment in age-related macular degeneration can masquerade as neovascularization on optical coherence tomography angiography
por: Chen, Ling, et al.
Publicado: (2018)

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials
por: Takahashi, Kanji, et al.
Publicado: (2023)

Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD
por: Fassnacht-Riederle, Heidi, et al.
Publicado: (2014)

Final 4-year results of the RAINBOW real-world study: intravitreal aflibercept dosing regimens in France in treatment-naïve patients with neovascular age-related macular degeneration
por: Cohen, Salomon-Yves, et al.
Publicado: (2022)

Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography
por: Clemens, C. R., et al.
Publicado: (2020)

Importance of continuous treatment with intravitreal aflibercept injections in patients with neovascular age-related macular degeneration—12-month post hoc analysis of the PERSEUS real-world evidence study
por: Wachtlin, Joachim, et al.
Publicado: (2020)

PERSEUS-IT 24-month analysis: a prospective observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Italy in patients with neovascular age-related macular degeneration
por: Nicolò, Massimo, et al.
Publicado: (2022)

Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19
por: Stone, Lydia G., et al.
Publicado: (2020)

PERSEUS 24-month analysis: a prospective non-interventional study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in Germany in patients with neovascular age-related macular degeneration
por: Eter, Nicole, et al.
Publicado: (2021)

Switching anti-VEGF agent for wet AMD: evaluation of impact on visual acuity, treatment frequency and retinal morphology in a real-world clinical setting
por: Granstam, Elisabet, et al.
Publicado: (2021)

Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study
por: Ohji, Masahito, et al.
Publicado: (2021)

The detrimental effects of delayed intravitreal anti-VEGF therapy for treating retinal pathology: lessons from a forced test-case
por: Navarrete, Ana, et al.
Publicado: (2022)

Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy
por: Schworm, Benedikt, et al.
Publicado: (2021)

Choroidal thickness in lamellar macular holes
por: Kal, Magdalena, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0vcn7fcig7obvkd4ng8892fss2